Trials / Completed
CompletedNCT00433693
Correction Study of R744 in Renal Anemia Patients on Hemodialysis
Correction Study of Intravenous Injections of R744 to Hemodialysis Patients ( Phase Ⅲ Study ).
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Chugai Pharmaceutical · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the efficacy and safety of intravenous R744 in renal anemia patients on hemodialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | R744 | 50μg(i.v.)/2 week until Hb concentration reaches to 11.0g/dL or above, then 25\~300μg(i.v.)/4 week |
Timeline
- Start date
- 2007-02-01
- Primary completion
- 2008-03-01
- Completion
- 2008-10-01
- First posted
- 2007-02-12
- Last updated
- 2009-02-02
Locations
6 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00433693. Inclusion in this directory is not an endorsement.